Loading viewer...
investor_presentation
Format: PDF investor_presentation
1 Wave Life Sciences Corporate Presentation July 29, 2019
Corporate Presentation
July 29, 20192Forward -looking statements
Thisdocument contains forward -looking statements .Allstatements other than statements ofhistorical facts contained inthis
document, including statements regarding possible orassumed future results ofoperations, preclinical andclinical studies,
business strategies, research anddevelopment plans, collaborations andpartnerships, regulatory activities andtiming thereof,
competitive position, potential growth opportunities, useofproceeds andtheeffects ofcompetition areforward -looking
statements .These statements involve known andunknown risks, uncertainties andother important factors thatmaycause
theactual results, performance orachievements ofWave LifeSciences Ltd.(the“Company”) tobematerially different from
anyfuture results, performance orachievements expressed orimplied bytheforward -looking statements .Insome cases, you
canidentify forward -looking statements byterms such as“may,” “will,” “should,” “expect,” “plan,” “aim,” “anticipate,” “could,”
“intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential” or“continue” orthenegative ofthese
terms orother similar expressions .Theforward -looking statements inthispresentation areonlypredictions .TheCompany has
based these forward -looking statements largely onitscurrent expectations andprojections about future events andfinancial
trends thatitbelieves mayaffect theCompany’s business, financial condition andresults ofoperations .These forward -looking
statements speak onlyasofthedateofthispresentation andaresubject toanumber ofrisks, uncertainties andassumptions,
including those listed under RiskFactors intheCompany’s Form 10-Kandother filings withtheSEC, some ofwhich cannot be
predicted orquantified andsome ofwhich arebeyond theCompany’s control .Theevents andcircumstances reflected inthe
Company’s forward -looking statements maynotbeachieved oroccur, andactual results could differ materially from those
projected intheforward -looking statements .Moreover, theCompany operates inadynamic industry andeconomy .Newrisk
factors anduncertainties mayemerge from timetotime, anditisnotpossible formanagement topredict allriskfactors and
uncertainties thattheCompany mayface.Except asrequired byapplicable law,theCompany does notplantopublicly update
orrevise anyforward -looking statements contained herein, whether asaresult ofanynew information, future events,
changed circumstances orotherwise .3
STEREOCHEMISTRYCHEMISTRYTargeting genetically defined diseases with
stereopure oligonucleotides
Building fully integrated genetic medicines company led by neurology development programs
•Lead clinical program: Suvodirsen
Phase 2/3 trial initiated for DMD
(exon 51); program on development path toward US and global approvals
•Advancing additional exon skipping candidates for DMD
Preview truncated — download the full document for the complete content.
investor_presentation
5 Pages
investor_presentation
15 Pages
Genius Group
Solomon Technology Corporation (2359) Investor Presentation
investor_presentationinvestor_presentation
34 Pages
Solomon Technology Corporation